Score Card for China Biologic Products (CBPO)

 China Biologic Products
Shares Outstanding (MRQ): 25.68 mill
Fully diluted shares outstanding (most recent quarter, SEC filing)
POSITIVE: under 30 million shares  |  NEGATIVE: over 50 million shares
New Shares / Dilution (TTM): -0.79 mill-2.99%
Newly issued shares in the past 12 months (most recent quarter, SEC filing)
POSITIVE: under 10% dilution  |  NEGATIVE: over 30% dilution
Cash (MRQ): 56.31 mill2.21%
Cash and cash equivalents, excl. restricted cash (most recent quarter, SEC filing)
POSITIVE: over 30% of market capitalization  |  NEGATIVE: under 10% of market capitalization
Account Receivables (MRQ): 13.31 mill0.52%
Account/Trade receivables (most recent quarter, SEC filing)
POSITIVE: under 10% of market capitalization  |  NEGATIVE: over 30% of market capitalization
Account Receivables (Q/Q): + 3.18 mill 
Quarterly increase/decrease of account/trade receivables (most recent quarter, SEC filing)
POSITIVE: quarterly decrease  |  NEGATIVE: quarterly increase of 20% or more
Relevant only if A/R to market capitalization ration higher than 10%
Long-Term Debt (MRQ): 4.42 mill0.17%
Long-term debt excl. warrant liabilities (most recent quarter, SEC filing)
POSITIVE: under 5% of market capitalization  |  NEGATIVE: over 20% of market capitalization
Revenue Growth (Q/Q): -3.40% 
Revenue Growth (Y/Y): 27.21% 
Total revenue growth year-over-year (most recent quarter, SEC filing)
POSITIVE: over 30% revenue growth  |  NEGATIVE: negative revenue growth
Net Income Growth (Q/Q): 5.99% 
Net Income Growth (Y/Y): 5.16% 
Net income growth year-over-year (most recent quarter, SEC filing)
POSITIVE: over 20% net income growth  |  NEGATIVE: negative net income growth
EPS Growth (Y/Y): 8.40% 
EPS growth year-over-year (most recent quarter, SEC filing)
POSITIVE: over 10% EPS growth  |  NEGATIVE: negative EPS growth
EPS | P/E (2 MRQ Projection): $1.2182.12
Projected trailing annual EPS using the two most recently reported quarters
POSITIVE: P/E under 6 / 8 / 10  |  NEGATIVE: P/E over 12
CFPS | P/CF (2 MRQ Projection): $0.81122.59
Projected trailing annual Operating Cash Flow per Share using the two most recently reported quarters
POSITIVE: P/CF under 6 / 8 / 10  |  NEGATIVE: P/CF over 12
Price/Sales (2 MRQ Projection): 18.12
Projected trailing annual sales using the two most recently reported quarters
POSITIVE: Price/Sales ratio under 1.25  |  NEGATIVE: Price/Sales ratio over 2.5
Price/Book (MRQ): 24.74
Market capitalization / total stockholders' equity (most recent quarter, SEC filing)
POSITIVE: Price/Book ratio under 1.25  |  NEGATIVE: Price/Book ratio over 2.5
Recent High | Trading near Highs: $11.00800.00%
Difference between current price and recent (3-6 months) high
POSITIVE: current price within 20% of recent highs
Recent Low | Trading near Lows: $7.071,300.28% 
Difference between current price and recent (3-6 months) low
NEGATIVE: current price within 20% of recent lows
Forward EPS | P/E Projection (Estimates): $1.7058.24
Projected forward EPS (Trading China estimates)
POSITIVE: P/E under 4 / 6 / 8  |  NEGATIVE: P/E over 10
Auditor: KPMG
The Company's independent registered public accounting firm
POSITIVE: Top 10 ranked  |  NEGATIVE: not ranked in the Top 100
CBPO
Healthcare & Drugs
SCORE
0
READ: Score Cards Explained
SAFETY/RISK SCORE
MODERATE RISK
DETAILS: Safety/Risk Model for CBPO
Current Price:  $99.00
2008 Close: 2,368.82%$4.01
2009 Close: 719.53%$12.08
High (2012-07-20): 800.00%$11.00
Low (2012-05-25): 1,300.28%$7.07
Market Capitalization: 2,542.38 mill
Last Quarter: 2011-03-31
Revenue (MRQ): 34.47 mill
Net Income (MRQ): 7.97 mill
Op. Cash Flow (MRQ): 2.88 mill
all financial data provided without warranty